1-5 of 5
Pavla Kadlecova
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Long-Term Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Polycythemia Vera — Final Phase I/II Peginvera Study Results

Heinz Gisslinger, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Forjan, MD, Ella Willenbacher, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Margarete Stampfl-Mattersberger, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Martin Schalling, MSc, Maria-Theresa Krauth, MD, Richard Greil, MD, Pavla Kadlecova, Michael Zoerer, Victoria Empson, MSc, Barbara Grohmann-Izay, MD MSc, Christoph Klade, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3030.
https://doi.org/10.1182/blood-2018-99-118584
Published: 2018
Journal Articles

Long Term Efficacy and Safety Results and Analysis of Dose Correlations from the Phase I/II Peginvera Study of Ropeginterferon Alfa-2b, a Novel IFNa-2b, in Polycythemia Vera Patient

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, Josef Thaler, MD, Ernst Schlögl, MD, Gunther Gastl, MD Prof,, Dominik Wolf, MD, Martin Schalling, MSc, Bettina Gisslinger, Sarita Ban, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, Maria Theresa Krauth, MD, Nicole C.C. Them, Robert Kralovics, PhD, Michael Zörer, Oliver Ammann-Mwathi, Pavla Kadlecova, Oleh Zagrijtschuk, Christoph Klade, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 4056.
https://doi.org/10.1182/blood.V126.23.4056.4056
Published: 2015
Journal Articles

Four Weeks Administration Schedule of Ropeginterferon Alfa-2b (AOP2014/P1101) in Polycythemia Very Patients Allows Maintaining of Efficacy with Favorable Toxicity Profile in the Phase I/II Peginvera Stud

Veronika Buxhofer-Ausch, Heinz Gisslinger, MD, Josef Thaler, MD, Ernst Schlögl, MD, Gunther Gastl, MD Prof, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, Sarita Ban, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Martin Schalling, MSc, Maria Theresa Krauth, MD, Nicole C.C. Them, Michael Zörer, Oliver Ammann-Mwathi, Pavla Kadlecova, Oleh Zagrijtschuk, Christoph Klade, Richard Greil, MD
Journal: Blood
Blood (2015) 126 (23): 1603.
https://doi.org/10.1182/blood.V126.23.1603.1603
Published: 2015
Journal Articles

Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera

Clinical Trials & Observations
Heinz Gisslinger, Oleh Zagrijtschuk, Veronika Buxhofer-Ausch, Josef Thaler, Ernst Schloegl, Guenther A. Gastl, Dominik Wolf, Robert Kralovics, Bettina Gisslinger, Karin Strecker, Alexander Egle, Thomas Melchardt, Sonja Burgstaller, Ella Willenbacher, Martin Schalling, Nicole C. Them, Pavla Kadlecova, Christoph Klade, Richard Greil
Journal: Blood
Blood (2015) 126 (15): 1762–1769.
https://doi.org/10.1182/blood-2015-04-637280
Published: 2015
Includes: Supplemental data
Journal Articles

Switch from Every Two Weeks to Every Four Weeks Administration Schedule of AOP2014, an Innovative Pegylated Interferon Alpha, in Polycythemia Very Patients Allows Maintaining of Efficacy with Improved Toxicity Profile in Phase I/II Study

Heinz Gisslinger, MD, Veronika Buxhofer-Ausch, MD, Josef Thaler, MD, Ernst Schloegl, MD, Guenther A. Gastl, MD, Dominik Wolf, MD, Robert Kralovics, PhD, Bettina Gisslinger, MSc, Karin Strecker, MD, Alexander Egle, MD, Thomas Melchardt, MD, Sonja Burgstaller, MD, Ella Willenbacher, MD, Michael Zoerer, PhD, Pavla Kadlecova, PhD, Oleh Zagrijtschuk, MD, Christoph Klade, PhD, Richard Greil, MD
Journal: Blood
Blood (2014) 124 (21): 3177.
https://doi.org/10.1182/blood.V124.21.3177.3177
Published: 2014